Argent Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Argent Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-68,470	Closed	-$2.27M	–	205
2019 Q2	$2.27M	Buy	68,470 +1,250	+2%	+$42.8K	0.09%	106
2019 Q1	$2.35M	Sell	67,220 -8,600	-11%	-$320K	0.09%	97
2018 Q4	$2.52M	Sell	75,820 -150	-0.2%	-$6.45K	0.13%	87
2018 Q3	$3.83M	Hold	75,970	–	–	0.13%	77
2018 Q2	$4.55M	Buy	75,970 +6,205	+9%	+$321K	0.16%	68
2018 Q1	$3.19M	Buy	69,765 +315	+0.5%	+$13.1K	0.12%	88
2017 Q4	$2.71M	Hold	69,450	–	–	0.09%	103
2017 Q3	$2.78M	Sell	69,450 -22,175	-24%	-$960K	0.11%	98
2017 Q2	$3.95M	Buy	91,625 +2,675	+3%	+$95.2K	0.16%	79
2017 Q1	$2.78M	Buy	88,950 +4,950	+6%	+$133K	0.11%	99
2016 Q4	$2.12M	Buy	+84,000	New	+$1.88M	0.09%	109

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Argent Capital Management's SUPN Position: Q3 2019 in Review

Argent Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 68,470 shares — an estimated $2.27M sold.

Argent Capital Management first reported a position in SUPN in Q4 2016 and held it in 11 quarters. The position peaked at $4.55M in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Argent Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Argent Capital Management sold 68,470 Supernus Pharmaceuticals shares in Q3 2019, an estimated $2.27M.
Argent Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 11 quarters.
Argent Capital Management's Supernus Pharmaceuticals position peaked at $4.55M in Q2 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Argent Capital Management's 13F filing for Q3 2019, filed 7 Nov 2019.